Navigation Links
New study on Hepatitis C drug treatment in vivo and in vitro
Date:2/18/2013

Hepatitis C virus (HCV) infection affects about 4.1 million in the United States and is the primary cause of liver cirrhosis and liver cancer. Current therapy against HCV is suboptimal. Daclatasvir, a direct acting antiviral (DAA) agent in development for the treatment of HCV, targets one of the HCV proteins (i.e., NS5A) and causes the fastest viral decline (within 12 hours of treatment) ever seen with anti-HCV drugs. An interdisciplinary effort by mathematical modelers, clinicians and molecular virologists has revealed that daclatasvir has two main modes of action against HCV and also yields a new, more accurate estimate of the HCV half-life.

Results of the NS5A study are published in the prestigious Proceedings of the National Academy of Sciences (PNAS) on February 18th, 2013.

"Ultimately, our study will help design better DAA drug cocktails to treat HCV," said Loyola University Health System (LUHS) and Stritch School of Medicine (SSOM) mathematical modeler Harel Dahari, Ph.D, who co-led the study. Dahari is one of five members of the Division of Hepatology at Loyola headed by Scott Cotler, MD who authored the study along with Thomas Layden, MD, HCV virologist Susan L. Uprichard, Ph.D and Dr. Uprichard's Ph.D graduate student Natasha Sansone. The study was co-led with Dr. Jeremie Guedj (Institut National de la Sant et de la Recherche Mdicale), and conducted with Drs. Alan Perelson (Senior Fellow at Los Alamos National Laboratory), Libin Rong (Oakland University) and Richard Nettles (Bristol-Myers Squibb).

The new study documents HCV kinetic modeling during treatment both in patients and in cell culture that provides insight into the modes of action of daclatasvir. In addition, the study suggests a more accurate estimate of HCV clearance from circulation previously estimated in 1998 by Drs. Dahari, Layden, Perelson and colleagues in Science.

"Our modeling of viral kinetics in treated patients predicts that daclatasvir not only blocks the synthesis of the viral RNA within infected cells but also blocks the secretion of infectious virus from the cells," explained Dahari. This prediction was confirmed in Dr. Uprichard's laboratory using cultured liver cells that support the entire life cycle of HCV infection. Drs. Dahari and Uprichard are directors of a new program for experimental and translational modeling recently established at Loyola to promote the type of interdisciplinary research exemplified in this publication.

Additional 2013 Dahari Research Papers

Additional research conducted by Dahari and colleagues related to the new Loyola program for experimental and translational modeling are in press for publication in other professional journals:

  • A study on the effect of ribavirin on HCV kinetics and liver gene expression, led by researchers from the National Institute of Health and published in Gut.

  • A letter on understanding triphasic HCV decline during treatment in the era of IL28B polymorphisms and direct acting antiviral agents via mathematical modeling, published in the Journal of Hepatology.

  • A study showcasing a mathematical model of the acute and chronic phases of Theiler murine encephalomyelitis virus (TMEV) infection that can serve as an important tool in understanding TMEV infectious mechanisms and may prove useful in evaluating antivirals and/or therapeutic modalities to prevent or inhibit demyelination multiple sclerosis, published in the Journal of Virology.

Dr Dahari is a recognized international leader in the field of viral kinetics. "Loyola is honored to have Dr. Dahari as a member of the Hepatology faculty; his ground-breaking research will help reinforce Loyola's leadership in the treatment of hepatitis C," said David Hecht, MD, interim senior vice president, Clinical Affairs at LUHS and Chair of Internal Medicine in the SSOM.


'/>"/>

Contact: Stasia Thompson
thoms@lumc.edu
708-216-5155
Loyola University Health System
Source:Eurekalert

Related medicine news :

1. Smoggy Air Tied to Heart Attacks: Study
2. Proscar Wont Boost Prostate Cancer Survival, Study Finds
3. Bel Marra Health Reports on a New Study: Body Image Influences Psychosocial Activities and Quality of Life.
4. New Study Finds Eating More Colorful Produce May Prevent or Delay ALS, Underscores Value of Health Enhancement Systems Program Design
5. MRSA Super Bug Prevalent in Nursing Homes, Study Finds
6. Study finds possible link between diabetes and increased risk of heart attack death
7. Rich/Poor Divide Linked to Hospital Readmissions in Study
8. NIH study shows big improvement in diabetes control over past decades
9. Alcohol Blamed for 1 in Every 30 Cancer Deaths: Study
10. Public Smoking Bans Cut Risk of Preterm Births, Study Finds
11. Yumi Media Reacts to Study Showing Benefits of Veganism for Fibromyalgia Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... 2017 , ... Hamlin Dental Group and Dr. Hamid Reza, dentist in ... the month of February, patients who visit Hamlin Dental Group will receive a ticket ... two at the Cheesecake Factory. , Tickets are available for routine dental visits ...
(Date:2/23/2017)... ... 23, 2017 , ... On April 13, 2017, The ... “Doping in Sport: How the Culture Might Change,” in conjunction with Pepperdine ... will be held at Pepperdine University in Malibu, California. , Sir Philip Craven, ...
(Date:2/23/2017)... ... 2017 , ... ERT, a global data and technology company ... a leading clinical development service provider, has selected ERT’s Trial Oversight suite as ... part to an array of circumstances including the use of multiple data capture ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Center for Autism ... Consortium for Autism Research and Treatment (RI-CART) and Cinemaworld to present Sensory Friendly ... (ASD) to see films in an environment that accommodates their unique needs. , ...
(Date:2/23/2017)... ... February 23, 2017 , ... Top cosmetic and periodontal ... program today with a new Indiegogo campaign . Individuals are now able ... in the Los Angeles area, either as a participating patient or through an Indiegogo ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Medical, Inc. (NASDAQ: CGNT), a medical device company that ... urology market, will release financial results for the fourth ... the market open on Thursday, March 9, 2017. ... and webcast to discuss its financial results the same ... Eastern Time (10:00 a.m. Central Time). Darin Hammers ...
(Date:2/23/2017)... 23. Februar 2017 Im Rahmen seiner ... Wirtschaftszone in der südwestlichen chinesischen Provinz Guizhou, 2017 mit dem ... Innovationsplattform aktiv an der Entwicklung einer eingebetteten Hightech-Schlüsselindustrie. ... Continue Reading ... ...
(Date:2/23/2017)... Calif. , Feb. 23, 2017 ... leading the discovery and development of innovative medicines targeting ... full year 2016 financial results on Thursday, March 2, ... host a conference call and webcast on March 2, ... quarter and full year 2016 financial results and provide ...
Breaking Medicine Technology: